

To
The General Manager
Department of Corporate Services,
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 526139

Respected Sir / Madam,

Sub: **Outcome of Board Meeting.**

This has reference to our letter dated 17th July 2023.

At the meeting of the Board of Directors of the company held on 05th August 2023 the following decisions were taken:

- 1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) along with Limited Review Report of the Company for the quarter ended on 30th June. 2023.
- 2) The Board considered and approved the closure of subsidiary company M/s. Peroral Bio Private Limited.
- 3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year 2022-23.
- 4) The Board considered and approved the appointment of M/s. Geeta Serwani & Associates, Practicing Company Secretaries as the Secretarial Auditor of the Company for the financial year 2022-2023.
- 5) The Board considered and approved the appointment of Ms. Vasavi & Co, as Internal Auditors of the Company for the financial year 2022-23.
- 6) The Board considered and approved the opening of a bank account.

The meeting commenced at 11.00 A.M and concluded at 12.00 P.M.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED



DRK KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Encls: as above

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Audited)	31.03.2023 (Audited)
1	Revenue from operations	9,98,710	-	5,50,847	5,50,847
2	Other income (net)	4,38,470	4,38,470	4,38,470	17,53,880
3	Total income (1 + 2)	14,37,180	4,38,470	9,89,317	23,04,727
4	EXPENSES				
	Cost of materials consumed	-	31,648	7,204	54,546
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	6,08,617	-	6,08,617
	Employee benefits expense	7,86,312	7,86,312	7,46,157	30,37,608
	Finance costs	3,22,838	4,53,410	4,53,410	18,13,638
	Depreciation and amortisation expense	2,30,847	123,74,307	123,74,307	495,00,842
	Other expenses	14,12,187	8,97,288	12,90,740	73,73,161
	Total expenses	27,52,184	151,51,582	148,71,818	623,88,413
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(13,15,004)	(147,13,112)	(138,82,501)	(600,83,686)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(13,15,004)	(147,13,112)	(138,82,501)	(600,83,686)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(13,15,004)	(147,13,112)	(138,82,501)	(600,83,686)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(13,15,004)	(147,13,112)	(138,82,501)	(600,83,686)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.02)	(0.19)	(0.18)	(0.79)
	Diluted (Rs.)	(0.02)	(0.19)	(0.18)	(0.79)

Notes:

- The management is informed by NidFree Management about various ongoing discussions with foreign companies for oral and nasal delivery of injectable molecules.
- Next date for SAT hearing is fixed for 4th September 2023.
- Our legal course for reclaiming the lost GDR funds will be reactivated shortly after transferring the pending payment to our legal team in London.
- We have not received any communication from Enforcement Directorate after Adjudication Hearing on 24th April 2023.
The MD, Dr. Koteswara Rao is to appear at the local Magistrate Court on the matter relating to the death of Mr. Uma Maheswara Rao, one of the scientists who died in 2014 as a result of chemical explosion during a drug production process
- No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 5th August 2023

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director

 Date: 05/08/2023
 Place: Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Standalone financial statements****Other expenses**

Particulars	For the Period ended June 30,2023
BSNL Fiber net	3,700
Conveyance Expenses	700
Directors sitting fee	10,000
Legal and Professional Charges	5,94,764
Miscellaneous Expenses	1,500
Office Expenses	29,894
Patents Application fee	2,68,386
Postage and Courier Expenses	1,560
Power and Fuel	10,978
Printing and Stationary	370
Rates, taxes and duties	3,100
Repairs and maintenance	3,180
SEBI Expenses	4,75,000
Telephone Expenses	1,955
Transport charges	2,400
Travelling Expenses	4,700
Total	14,12,187

For TRANSGENE BIOTEK LIMITED**Dr.K.Koteswara Rao**
Managing Director

Date: 05/08/2023

Place:Hyderabad

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Audited)	31.03.2023 (Audited)
1	Revenue from operations	9,98,710	-	5,50,847	5,50,847
2	Other income (net)	4,38,470	4,38,470	4,38,470	17,53,880
3	Total income (1 + 2)	14,37,180	4,38,470	9,89,317	23,04,727
4	EXPENSES				
	Cost of materials consumed	-	31,648	7,204	54,546
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	6,08,617	-	6,08,617
	Employee benefits expense	7,86,312	7,86,312	7,46,157	30,37,608
	Finance costs	3,22,838	4,53,410	4,53,410	18,13,638
	Depreciation and amortisation expense	2,30,847	123,74,307	123,74,307	495,00,842
	Other expenses	14,85,906	8,99,588	12,90,740	73,75,461
	Total expenses	28,25,903	151,53,882	148,71,818	623,90,713
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(13,88,723)	(147,15,412)	(138,82,501)	(600,85,986)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(13,88,723)	(147,15,412)	(138,82,501)	(600,85,986)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(13,88,723)	(147,15,412)	(138,82,501)	(600,85,986)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(13,88,723)	(147,15,412)	(138,82,501)	(600,85,986)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.02)	(0.19)	(0.18)	(0.79)
	Diluted (Rs.)	(0.02)	(0.19)	(0.18)	(0.79)

Notes:

- The management is informed by NidFree Management about various ongoing discussions with foreign companies for oral and nasal delivery of injectable molecules.
 - Next date for SAT hearing is fixed for 4th September 2023.
 - Our legal course for reclaiming the lost GDR funds will be reactivated shortly after transferring the pending payment to our legal team in London.
 - We have not received any communication from Enforcement Directorate after Adjudication Hearing on 24th April 2023.

The MD, Dr. Koteswara Rao is to appear at the local Magistrate Court on the matter relating to the death of Mr. Uma Maheswara Rao, one of the scientists who died in 2014 as a result of chemical explosion during a drug production process
 - No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 5th August 2023

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director

 Date: 05/08/2023
 Place: Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Consolidated financial statements****Other expenses**

Particulars	For the Period ended June 30,2023
BSNL Fiber net	3,700
Conveyance Expenses	700
Directors sitting fee	10,000
Legal and Professional Charges	6,67,764
Miscellaneous Expenses	2,219
Office Expenses	29,894
Patents Application fee	2,68,386
Postage and Courier Expenses	1,560
Power and Fuel	10,978
Printing and Stationary	370
Rates, taxes and duties	3,100
Repairs and maintenance	3,180
SEBI Expenses	4,75,000
Telephone Expenses	1,955
Transport charges	2,400
Travelling Expenses	4,700
Total	14,85,906

For TRANSGENE BIOTEK LIMITED**Dr.K.Koteswara Rao****Managing Director**

Date: 05/08/2023

Place:Hyderabad





MANISHA DUBEY & ASSOCIATES

CHARTERED ACCOUNTANTS

Limited Review Report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 30 June 2023 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain
- 2-4-1096, Ground Floor, Nimbolliadda, Kachiguda, Hyderabad TS-500027



MANISHA DUBEY & ASSOCIATES

CHARTERED ACCOUNTANTS

assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities

Name of the entity	Relationship
1. Transgene Biotek HK Limited	Subsidiary
2. PerOral Bio Private Limited	Subsidiary

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2023 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

2-4-1096, Ground Floor, Nimbolliadda, Kachiguda, Hyderabad TS-500027

☎ 9440573588 / 7799001213 email:manishadubey.associates@yahoo.co.in



MANISHA DUBEY & ASSOCIATES

CHARTERED ACCOUNTANTS

7. We did not review the interim financial results of two subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 June 2023, as considered in the consolidated unaudited financial results.

For ManishaDubey& Associates
Chartered Accountants
FRNo.010114S



ManishaDubey
Proprietor
M No.212664
Place: Hyderabad
Date: 05.08.2023

**Unique Document Identification Number (UDIN) for this document is
23212664BGZHKH2214**

2-4-1096, Ground Floor, Nimbolliadda, Kachiguda, Hyderabad TS-500027

☎ 9440573588 / 7799001213 email:manishadubey.associates@yahoo.co.in



MANISHA DUBEY & ASSOCIATES

CHARTERED ACCOUNTANTS

Limited review report

To,

The Board of directors

M/s. Transgene Biotek Limited

Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 30 June 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting". - ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2023 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

2-4-1096, Ground Floor, Nimboliadda, Kachiguda, Hyderabad TS-500027

☎ 9440573588 / 7799001213 email:manishadubey.associates@yahoo.co.in



MANISHA DUBEY & ASSOCIATES

CHARTERED ACCOUNTANTS

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates
Chartered Accountants
FR No. 010114S



Manisha Dubey
Proprietor
M No. 212664
Place: Hyderabad
Date: 05.08.2023

**Unique Document Identification Number (UDIN) for this document is
23212664BGZHKH2214**

2-4-1096, Ground Floor, Nimbolliadda, Kachiguda, Hyderabad TS-500027

☎ 9440573588 / 7799001213 email: manishadubey.associates@yahoo.co.in